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Abstract 
Background: Artemisinin-based combination therapy is the recommended first-line treatment for uncomplicated 
falciparum malaria worldwide. However, recent studies conducted in Mali showed an increased frequency of recur-
rent parasitaemia following artemether–lumefantrine (AL) treatment.
Methods: Study samples were collected during a large WANECAM study. Ex-vivo Plasmodium falciparum sensitiv-
ity to artemether and lumefantrine was assessed using the tritiated hypoxanthine-based assay. The prevalence of 
molecular markers of anti-malarial drug resistance (pfcrt K76T, pfmdr1 N86Y and K13-propeller) were measured by PCR 
and/or sequencing.
Results: Overall 61 samples were successfully analysed in ex vivo studies. Mean IC50s increased significantly between 
baseline and recurrent parasites for both artemether (1.6 nM vs 3.2 nM, p < 0.001) and lumefantrine (1.4 nM vs 3.4 nM, 
p = 0.004). Wild type Pfmdr1 N86 allele was selected after treatment (71 vs 91%, 112 of 158 vs 95 of 105, p < 0.001) but 
not the wild type pfcrt K76 variant (23.5 vs 24.8%, 40 of 170 vs 26 of 105, p = 0.9). Three non-synonymous K13-propel-
ler SNPs (A522C, A578S, and G638R) were found with allele frequencies <2%.
Conclusion: Malian post-AL P. falciparum isolates were less susceptible to artemether and lumefantrine than baseline 
isolates.
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Background
Artemisinin-based combination therapy (ACT) is cur-
rently the first-line treatment for uncomplicated falcipa-
rum malaria worldwide, in both the public and private 
sectors [1, 2]. Lumefantrine has never been used alone 
in people [3]. Studies of in  vitro susceptibility of Plas-
modium falciparum to lumefantrine from West African 
countries showed IC50 ten times below the resistance 
threshold of 150  nM [4–7], while P. falciparum isolates 
from South-East Asia show higher mean IC50 that are 
closed to that threshold [8].
Several studies have investigated the role of pfmdr1 
gene in lumefantrine tolerance. Sisowath et  al. [9, 10] 
and Baliraine et al. [11] reported that lumefantrine pres-
sure provides the main selective force on the pfmdr1 N86 
allele and leads to resistance to lumefantrine. Happi et al. 
[12] reported that the pfmdr1_ N86_ F184_ D1246 (NFD) 
haplotype rose from 10% in baseline samples to 75% in 
breakthrough parasites, an indication of its enhanced 
survival fitness. Similar observations were reported in 
three different studies in East Africa [11, 13, 14]. Fur-
thermore, an association between lumefantrine IC50 and 
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Lumefantrine was shown to have synergistic interac-
tion with artemisinin derivatives in  vitro in continuous 
culture [16]. Hence, artemether was the first artemisinin 
derivative to be combined in fixed dose with a partner 
drug as artemether–lumefantrine. Delayed parasite clear-
ance is the phenotype of in vivo resistance to artemisinin 
and its derivatives in the field [17]. Witkowski et al. [18] 
reported that increased tolerance to artemisinin in vitro 
was seen in quiescent P. falciparum parasite from Thai-
land–Cambodia border. Noedl et  al. [19] reported the 
first cases of artemisinin resistance in vitro in Cambodia.
A reduced susceptibility of P. falciparum to artemisinin 
was not detected in mature forms but in young ring 
stages [20]. The in  vitro and ex  vivo ring stage survival 
assay (RSA) on 0–3 h rings (RSA0–3) correlated best with 
in  vivo artemisinin resistance as measured by delayed 
parasite clearance [21]. Flow cytometry-based ring-stage 
survival assay performs as well as light microscopy and 
can be used to standardize the collection of RSA data for 
P. falciparum artemisinin resistance between research 
groups in laboratory and field settings [22].
Recent studies have identified P. falciparum Kelch 13 
(pfK13) polymorphisms to be associated with delayed 
parasite clearance time after ACT in Southeast Asia [23]. 
Three key point mutations in the pfK13 gene were asso-
ciated with delayed clearance of P. falciparum following 
artemisinin treatment in Southeast Asia [24]. Most stud-
ies assessing the relationship between delayed parasite 
clearance time and K13 mutations have been conducted 
in Asia. The possibility that artemisinin resistance might 
also appear or introduced in sub-Saharan Africa neces-
sitates careful surveillance through periodic in  vivo 
and ex vivo efficacy studies in malaria endemic regions. 
Although several studies of the efficacy of artemether–
lumefantrine in Africa showed high efficacy after molec-
ular correction, the cure rate without PCR correction 
was lower [25–29]. Similarly, studies in Mali showed a 
significant number of recurrent parasitaemia following 
artemether–lumefantrine (AL) treatment [30, 31]. The 
study hypothesis was that these recurrent parasites are 
less sensitive to AL in ex vivo study.
Methods
Sample collection
Blood samples were collected from the patient enrolled 
in artemether–lumefantrine arm during the large ongo-
ing network study [32]. Briefly 2–3  ml of blood was 
obtained by venipuncture from patient with P. falciparum 
mono-infections at least 2250 trophozoites per μl (0.05%) 
or greater parasitaemia by using the EDTA Vacutainer® 
tubes. Day 0 samples were collected before treatment 
administration and independents Day recurrent parasites 
samples were collected after treatment initiation between 
Day  28 and Day  42. Samples were transported by car 
from Sotuba and Kollé to the Culture Room of Malaria 
Research and Training Centre at 4–8  °C where ex  vivo 
has been done. All samples were cultivated ex vivo imme-
diately or for no longer than 24 h.
Drugs dilution and plate coating, preparation of culture 
media
Before sample collection, two anti-malarial drugs 
(artemether A9361-25MG, SIGMA and lumefantrine 
L5420-25MG) were dissolved and distributed in appro-
priate solutions (methanol and ethanol). The starting 
solutions were prepared from the powder contained in 
glass vials. Artemether was dissolved at a concentration 
of 0.1 mg/ml with methanol. Lumefantrine was dissolved 
in ethanol to have a concentration of 0.01 mg/ml. These 
starting solutions have been used directly or stored in 
freezer for the future use. Dilutions calculations were 
double checked before. All information about weight, 
solvent were recorded in laboratory book. The prepara-
tion of serial dilutions were made in sterile glass flask that 
allowed to have following concentrations (2.34–600  nM 
for artemether and 1.25–320  nM for lumefantrine). 
Each serial concentration have been made in triplicate 
in 96-well tissue culture plate and dried under a laminar 
flow hood. RPMI 1640 (R6504-10L) powder with l-gluta-
mate was dissolved in cell grade water and supplemented 
with sodium bicarbonate and HEPES. After checking pH, 
which should be 7.2 media was supplemented with 10% 
of human serum.
Ex vivo sensitivity testing
For ex  vivo drug sensitivity testing, a semi-automated 
radioactive microplate method was used to measure the 
IC50 as described in a previous study [33]. Briefly, at day 
0, ring-form parasites obtained after blood collection 
were washed three times in RPMI 1640 media. Infected 
Red blood cells were suspended in 10% human serum 
completed culture media. After adjustment of parasitae-
mia between 0.5 and 1% and hematocrit at 1%, an equiv-
alent of 1 μ Ci per well of tritiated hypoxanthine with a 
specific activity of 14.1  Ci/mmol (Perkin-Elmer, Foster 
City, CA) was added in a parasite suspension. A final vol-
ume of 200 μl per well of parasite suspension was placed 
into drug-prefilled 96-well tissue culture plates. The 
parasite suspension was mixed and incubated with each 
drug at various concentrations of drug at 37 °C with 5% 
CO2, 5% O2 and 90% N2 for 42 h. After one step of freez-
ing and thawing, the parasites were collected on filter 
plate, dried and 50 μl of scintillation cocktail (Optiphase 
Supermix; Perkin-Elmer) was added on each well. Trit-
ium incorporation was determined with a beta-counter 
(Wallac 1450 microbeta trilux; Perkin-Elmer), and the 
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IC50 was determined after the drug concentration was 
plotted against the radioactivity by the online IC50 esti-
mator [34]. Three wells without drug for each concentra-
tion panel and the reference clones 3D7 and Dd2 were 
used as control.
Molecular analysis
For the molecular analyses purpose dried blood spot 
samples (DBS) collected during the in  vivo study [32]. 
To evaluate the prevalence of molecular markers of drug 
resistance and discriminate reinfection from recrudes-
cence, DBS were used to extract parasite DNA using 
Qiagen mini kit (Qiagen, Valencia, CA) according to the 
manufacturer’s recommendations.
Plasmodium falciparum chloroquine-resistance trans-
porter (pfcrt) K76T and P. falciparum multidrug resist-
ance 1 (pfmdr1) N86Y mutations were genotyped in 
pre-treatment samples and in parasitaemia occurring 
in recurrent follow-up day [35]. A nested PCR strat-
egy based on previously published protocols [24, 36] 
was used to amplify a final 850 bp of the K13-propeller 
domain product (for PCR conditions see Ref. [36]). PCR 
products were sent to Macrogen Europe for sequencing. 
pfK13 sequence editing and analysis were conducted in 
Bamako, Mali.
Statistical analysis
IC50 values were analysed after logarithmic transforma-
tion and expressed as the geometric mean of the IC50 and 
the confidence interval 95% (95% CI). These continuous 
variables were compared using the independent Student’s 
t test. Prevalence of molecular markers of drug resistance 
was compared using the Chi Square test. All statistical 




Full in  vivo efficacy results for this study were reported 
elsewhere [32]. Overall 61 samples were successfully ana-
lysed in this ex vivo study. 38 samples were collected on 
day 0 before treatment initiation. Twenty-three samples 
were collected from recurrent parasites between day  28 
to day 42. All samples included in this study had para-
sitaemia at least 0.05% or greater parasitaemia. 20% of 
ex  vivo samples came from Kollé and 80% came from 
Sotuba. The geometric mean difference between pre-
treatment and post-treatment IC50 were 1.6  nM (95% 
CI, 1.4–1.9) vs 3.2 nM (95% CI, 2.5–4.2) for artemether 
(p < 0.01) and 1.4 nM (95% CI, 1.2–2.7) vs 3.4 nM (95% 
CI, 2.0–5.9) for lumefantrine (p = 0.004) (Table 1).
PCR–RFLP analyses of pfcrt K76T and pfmdr1 N86Y single 
nucleotide polymorphisms
Overall 275 samples were included for the molecular 
analysis. From which 170 samples were sample avail-
able at baseline and 105 were available at the follow-up 
day. 45% of the sample came from Kolle and 55% came 
from Sotuba. Prevalence of pfmdr1 and pfcrt alleles were 
compared between pre-treatment P. falciparum parasite 
isolates and parasites that emerged after treatment. At 
baseline pfcrt K76 was detected in 23.5% (40/170) while 
pfmdr1 N86 was detected in 71% (112/158) of P. falcipa-
rum isolates. After treatment with artemether–lumefan-
trine the prevalence of pfcrt K76 and pfmdr1 N86 were 
24.8% (26/105) and 91% (95/105), respectively (p  =  0.9 
for pfcrt and p  <  0.001 for pfmdr1) (Fig.  1). There was 
no statistically significant association between pfcrt 
K76 or pfmdr1 N86 and P. falciparum ex vivo responses 
(p > 0.05).
Kelch13‑propeller domain analysis
The K13-propeller domain sequences were generated 
from 192 samples collected in both Kolle and Sotuba 
(Genbank accession numbers AD1-AD167). Twenty-five 
samples had poor quality sequences and were excluded 
from this analysis. Using 3D7 as the reference strain, 
three low frequency non-synonymous SNPs were identi-
fied at codons A522C (1.2%), A578S (0.6%), and G638R 
(0.6%) in the K13-propeller domain. Three alleles were 
observed in Sotuba (3D7, A578S, G638R alleles) and two 
in Kolle (3D7, S522C allele).
Discussion
The finding of this study show that the ex  vivo efficacy 
of both artemether and lumefantrine was significantly 
reduced in post-AL parasites compared to pre-treatment 
parasites even though the respective IC50 were all within 
the respective sensitive ranges of each drug [37]. The 
geometric mean IC50 values of the artemether measured 
Table 1 Geometric mean IC50 before and after treatment for artemether and lumefantrine
a Confidence interval





Artemether 1.6 (1.4–1.9) 3.2 (2.5–4.2) <0.001
Lumefantrine 1.4 (1.2–1.7) 3.4 (2.0–5.9) 0.004
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in the present study are similar to published data from 
studies conducted in other Africans countries [7, 38, 
39]. Artemether mean IC50 was six times lower than the 
21.2 nM reported in a study conducted in South-Est Asia 
in 2011 [8]. Lumefantrine mean IC50 was lower than that 
reported in a previous study conducted in Mali [6] and 4 
times lower than the 15.1 nM reported in North-Western 
Thailand [40].
Although there was an increase in IC50 in post-AL 
parasites, in vivo study conducted at the same period of 
our sample collection found that the corrected clinical 
efficacy of oral artemether–lumefantrine remained high 
for the treatment of uncomplicated malaria [32]. All the 
samples tested ex vivo had an adequate clinical and para-
sitological response after molecular correction. These 
results were comparable to previous reports in others 
sites in Mali [30, 41, 42]. Similar finding was reported in 
artesunate monotherapy study conducted in Mali in 2010 
[25]. The cure rate was also similar to the 99% efficacy 
reported in a Kenyan study in 2010 [43]. These findings 
confirm that AL is still efficacious on malaria in Mali.
This study confirms previous findings of a selection of 
pfmdr1 N86 following artemether–lumefantrine treat-
ment [9–11, 44]. These molecular findings lend further 
support to the increased IC50 found for lumefantrine as 
pfmdr1 N86 was shown to be associated with P. falcipa-
rum in vitro resistance to lumefantrine [45]. The preva-
lence of pfcrt K76 allele remained stable after treatment 
with artemether–lumefantrine in this cohort study as 
reported in recent studies conducted in other Africans 
countries [46, 47]. The lack of difference of pfcrt wild type 
allele in this dataset between the days of failure compared 
to the baseline may probably be explained by the high 
prevalence of the mutant allele at baseline.
The prevalence of K13-propeller mutations was low in 
Malian parasite population. In vivo artemisinin resistance 
and delayed parasite clearance due to artemisinin resist-
ance have not been reported in Mali [44]. None of the 
mutations associated with prolonged parasite clearance 
time after artemisinin-based drugs reported in Cambo-
dia and other Southeast Asian countries were observed in 
Mali [24]. Of the three non-synonymous SNPs identified 
in this study only A578S was reported in previous stud-
ies in Mali [36, 48]; A522C and G638R have not yet been 
previously reported. All these SNPs were observed in the 
pre-treatment samples while no SNPs were observed in 
post-treatment samples.
The demonstrated continued efficacy of AL in this 
study has major implications for malaria control in West 
Africa. Indeed, AL is a centerpiece for malaria case-
management in the Sahel belt where current deploy-
ment of Seasonal Malaria Chemoprevention (SMC) with 
sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ) 
discourages the use of AQ containing ACTs. In addi-
tion, because AL selects the wild type allele pfmdr1 N86, 
which is associated with increased susceptibility to chlo-
roquine and AQ [49], the use of AL in malaria case man-
agement in West Africa would prolong the effectiveness 
of SPAQ for SMC.
Because of logistical constraints complete paired sam-
ple set were not obtained for most patients included in 
the ex  vivo assays while paired sample are ideally the 
best to do before and after. For these reasons independ-
ent Student’s t test was used to compare group before and 
after treatment.
Conclusion
Although AL is efficacious, ex  vivo P. falciparum 
decreased susceptibility and selection of pfmdr1 86Y 
indicate the need not only for aggressive monitor-
ing of parasite response to this mainstream ACT but 
also for the introduction of new types of ACT in this 
sub-region.
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